Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

Leukemia and Lymphoma

Volumn 54, Issue 8, 2013, Pages 1821-1822

  Cramer, Paula ^a   Fink, Anna Maria ^a   Busch, Raymonde ^b   Eichhorst, Barbara ^a   Wendtner, Clemens Martin ^c   Pflug, Natali ^a   Langerbeins, Petra ^a   Bahlo, Jasmin ^a   Goede, Valentin ^a   Schubert, Friederike ^a   Döhner, Hartmut ^d   Stilgenbauer, Stephan ^d   Dreger, Peter ^e   Kneba, Michael ^f   Böttcher, Sebastian ^f   Mayer, Jiri ^g   Hallek, Michael ^a   Fischer, Kirsten ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Klinikum Schwabing   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Chemoimmunotherapy; CLL; Relapse; Therapy

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONFERENCE PAPER; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PREDNISONE; TREATMENT OUTCOME; VIDARABINE; VINCRISTINE;

EID: 84880256495     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.796050     Document Type: Conference Paper

References (4)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010 ; 376 : 1164-1174
2. Robak T, Dmoszynska A, Solal-Celigny P, et a l. Rituximab plus fl udarabine and cyclophosphamide prolongs progression-free survival compared with fl udarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010 ; 28 : 1756-1765
3. Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011 ; 22(Suppl. 6) : Vi50-vi54
4. Fink A, Pfl ug N, Busch R, et a l. Serum factors predict therapeutic outcome in patients with chronic lymphocytic leukemia treated in the CLL8 trial of the German CLL Study Group (GCLLSG). Blood 2010; 116(Suppl. 1): Abstract 918